Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 2
2004 pubmed 272 citations

The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization.

Davidson. Donald J DJ; Currie. Andrew J AJ; Reid. Gregor S D GS; Bowdish. Dawn M E DM; MacDonald. Kelly L KL; Ma. Rebecca C RC; Hancock. Robert E W RE; Speert. David P DP

Key Findings

  • LL‑37 alters dendritic cell differentiation and boosts their ability to take up material
  • It increases expression of costimulatory molecules and Th‑1‑promoting cytokines
  • LL‑37‑treated dendritic cells drive stronger Th‑1 polarization in T cells

Practical Outcomes

  • LL‑37 looks promising as an immune‑modulating tool, but the research is still early and done in lab dishes. There’s no clear dosage or delivery method for personal use, so biohackers should wait for clinical studies before trying it as a supplement for health or performance.

Summary

The study shows that the natural peptide LL‑37 can change how immune cells called dendritic cells develop, making them better at grabbing stuff, showing more activation signals, and pushing other immune cells toward a Th‑1 type response, which is important for fighting infections.

Abstract

Dendritic cells (DC) are instrumental in orchestrating an appropriately polarized Th cell response to pathogens. DC exhibit considerable phenotypic and functional plasticity, influenced by lineage, Ag engagement, and the environment in which they develop and mature. In this study, we identify the human cationic peptide LL-37, found in abundance at sites of inflammation, as a potent modifier of DC differentiation, bridging innate and adaptive immune responses. LL-37-derived DC displayed significantly up-regulated endocytic capacity, modified phagocytic receptor expression and function, up-regulated costimulatory molecule expression, enhanced secretion of Th-1 inducing cytokines, and promoted Th1 responses in vitro. LL-37 may be an attractive therapeutic candidate for manipulating T cell polarization by DC.

Study Information

Provider

pubmed

Year

2004

Date

2004-01-15T00:00:00.000Z

DOI

10.4049/jimmunol.172.2.1146

Citations

272

References

48